{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:38Z","timestamp":1792177718028,"version":"4.4.0"},"reference-count":91,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Diabetes Australia Research Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with diabetes are disproportionately affected by cardiovascular and kidney disease. Mineralocorticoid receptor (MR) antagonists show organ protection against cardiovascular and renal injury; however, major side effects including hyperkalemia and reduced renal function limit their use in individuals with diabetic complications. The nonsteroidal MR modulator balcinrenone may offer end-organ protection with fewer side effects. We compared responses to balcinrenone and eplerenone delivered from 8 weeks postinduction of streptozotocin (STZ)-induced type 1 diabetes in male mice. RNA sequencing revealed diabetes induced modulation of immune function, and metabolic and vascular targets in the kidney, which were similarly attenuated by balcinrenone or eplerenone treatment. Urine K+ excretion was lower following eplerenone treatment, but not balcinrenone treatment, compared to diabetes without treatment. We identified a 5.90-fold increase in the expression of K+ transporter G protein-activated inward rectifier potassium channel 1 in eplerenone- but not balcinrenone-treated diabetic mice. Balcinrenone and eplerenone similarly attenuated the diabetes-induced reduction in peak E-wave\/A-wave velocity compared to mice without treatment at 15 weeks post-STZ. Gene markers of cardiac injury, B-type natriuretic peptide, and \u03b2-myosin heavy chain protein were higher in diabetic vs nondiabetic left ventricles (LVs). Conversely, gene expression of Ca2+ ion channel subunits, voltage-dependent L type, calcium channel subunit \u03b1 1C, and ryanodine receptor 2 in LV was lower in diabetic but not eplerenone- or balcinrenone-treated diabetic mice. Although balcinrenone and eplerenone similarly modified cardiac changes, potassium excretion was greater with balcinrenone, consistent with a reduced risk of hyperklemia with the nonsteroidal MR modulator.<\/jats:p>","DOI":"10.1210\/endocr\/bqaf178","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:41:19Z","timestamp":1769258479000},"source":"Crossref","is-referenced-by-count":2,"title":["Balcinrenone Shows a Unique Regulation of Potassium Excretion in Streptozotocin-induced Diabetes in Male Mice"],"prefix":"10.1210","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-3195","authenticated-orcid":false,"given":"Monica","family":"Kanki","sequence":"first","affiliation":[{"name":"Cardiovascular Endocrinology Laboratory, Discovery & Preclinical Domain, Baker Heart and Diabetes Institute , Melbourne, Victoria 3004 ,","place":["Australia"]},{"name":"Department of Medicine (Alfred Health), Central Clinical School, Monash University , Prahran, Victoria 3181 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott","family":"Vivekanantham","sequence":"additional","affiliation":[{"name":"Cardiovascular Endocrinology Laboratory, Discovery & Preclinical Domain, Baker Heart and Diabetes Institute , Melbourne, Victoria 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6137-3092","authenticated-orcid":false,"given":"Gregory H","family":"Tesch","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Monash University Department of Medicine, Monash Medical Centre , Clayton, Victoria 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9868-6914","authenticated-orcid":false,"given":"Adam C","family":"Parslow","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute Microscopy Platform, Baker Heart and Diabetes Institute , Melbourne, Victoria 3004 ,","place":["Australia"]},{"name":"Baker Department of Cardiometabolic Health, The University of Melbourne , Parkville, Victoria 3052 ,","place":["Australia"]},{"name":"Baker Department Cardiovascular Research, Translation and Implementation, La Trobe University , Bundoora, Victoria 3083 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J","family":"Cole","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University , Clayton, Victoria 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0948-2072","authenticated-orcid":false,"given":"Peter J","family":"Fuller","sequence":"additional","affiliation":[{"name":"Centre of Endocrinology and Metabolism, Hudson Institute of Medical Research , Clayton, Victoria 3168 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4924-720X","authenticated-orcid":false,"given":"Daniel G","family":"Donner","sequence":"additional","affiliation":[{"name":"Baker Department of Cardiometabolic Health, The University of Melbourne , Parkville, Victoria 3052 ,","place":["Australia"]},{"name":"Preclinical Cardiology Research Group, Baker Heart and Diabetes Institute , Melbourne, Victoria 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kiriazis","sequence":"additional","affiliation":[{"name":"Baker Department of Cardiometabolic Health, The University of Melbourne , Parkville, Victoria 3052 ,","place":["Australia"]},{"name":"Preclinical Cardiology Research Group, Baker Heart and Diabetes Institute , Melbourne, Victoria 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2749-7833","authenticated-orcid":false,"given":"Judy","family":"de Haan","sequence":"additional","affiliation":[{"name":"Baker Department of Cardiometabolic Health, The University of Melbourne , Parkville, Victoria 3052 ,","place":["Australia"]},{"name":"Cardiovascular Inflammation and Redox Biology Laboratory, Baker Heart and Diabetes Institute , Melbourne, Victoria 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June M","family":"Sun","sequence":"additional","affiliation":[{"name":"Cardiovascular Endocrinology Laboratory, Discovery & Preclinical Domain, Baker Heart and Diabetes Institute , Melbourne, Victoria 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0538-6083","authenticated-orcid":false,"given":"Krister","family":"Bamberg","sequence":"additional","affiliation":[{"name":"Early Cardiovascular, Renal, and Metabolism (CVRM) BioPharmaceuticals R&D, AstraZeneca , Gothenburg SE-431 83 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0450-5375","authenticated-orcid":false,"given":"Morag J","family":"Young","sequence":"additional","affiliation":[{"name":"Cardiovascular Endocrinology Laboratory, Discovery & Preclinical Domain, Baker Heart and Diabetes Institute , Melbourne, Victoria 3004 ,","place":["Australia"]},{"name":"Department of Medicine (Alfred Health), Central Clinical School, Monash University , Prahran, Victoria 3181 ,","place":["Australia"]},{"name":"Baker Department of Cardiometabolic Health, The University of Melbourne , Parkville, Victoria 3052 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"11","key":"2026050522164493800_bqaf178-B1","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ Res"},{"issue":"19","key":"2026050522164493800_bqaf178-B2","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"issue":"25","key":"2026050522164493800_bqaf178-B3","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehz149","article-title":"Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk","volume":"40","author":"Bohm","year":"2019","journal-title":"Eur Heart J"},{"key":"2026050522164493800_bqaf178-B4","doi-asserted-by":"crossref","first-page":"110973","DOI":"10.1016\/j.diabres.2023.110973","article-title":"Trends of hospitalisation for cardiovascular diseases among people with diabetes in Australia","volume":"205","author":"Elfu Feleke","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"2026050522164493800_bqaf178-B5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","article-title":"Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways","volume":"142","author":"Huynh","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"12","key":"2026050522164493800_bqaf178-B6","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2026050522164493800_bqaf178-B7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1463-1326.2007.00730.x","article-title":"Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS","volume":"10","author":"O'Keefe","year":"2008","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2026050522164493800_bqaf178-B8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1475-2840-12-172","article-title":"Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes","volume":"12","author":"Ramirez","year":"2013","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2026050522164493800_bqaf178-B9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/ehjci\/jeu013","article-title":"Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy","volume":"15","author":"Jellis","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026050522164493800_bqaf178-B10","doi-asserted-by":"crossref","first-page":"9232065","DOI":"10.1155\/2018\/9232065","article-title":"Spironolactone protects against diabetic cardiomyopathy in streptozotocin-induced diabetic rats","volume":"2018","author":"Liu","year":"2018","journal-title":"J Diabetes Res"},{"issue":"14","key":"2026050522164493800_bqaf178-B11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"2026050522164493800_bqaf178-B12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","article-title":"Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction","volume":"20","author":"Kurrelmeyer","year":"2014","journal-title":"J Card Fail"},{"issue":"11","key":"2026050522164493800_bqaf178-B13","first-page":"e19398","article-title":"Role of diabetes mellitus in heart failure with preserved ejection fraction: a review article","volume":"13","author":"Mgbemena","year":"2021","journal-title":"Cureus"},{"issue":"8","key":"2026050522164493800_bqaf178-B14","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026050522164493800_bqaf178-B15","doi-asserted-by":"crossref","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders\u2014new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"issue":"6","key":"2026050522164493800_bqaf178-B16","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"2026050522164493800_bqaf178-B17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"2026050522164493800_bqaf178-B18","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"issue":"16","key":"2026050522164493800_bqaf178-B19","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2026050522164493800_bqaf178-B20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"2026050522164493800_bqaf178-B21","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2026050522164493800_bqaf178-B22","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"issue":"2","key":"2026050522164493800_bqaf178-B23","doi-asserted-by":"crossref","first-page":"e0193380","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"2026050522164493800_bqaf178-B24","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bcp.13562","article-title":"Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator","volume":"84","author":"Erlandsson","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2026050522164493800_bqaf178-B25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cts.12705","article-title":"Safety, tolerability, and pharmacokinetics of the mineralocorticoid receptor modulator AZD9977 in healthy men: a phase I multiple ascending dose study","volume":"13","author":"Whittaker","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"8","key":"2026050522164493800_bqaf178-B26","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2026050522164493800_bqaf178-B27","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","article-title":"Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading","volume":"39","author":"Martinez","year":"2002","journal-title":"Hypertension"},{"issue":"4","key":"2026050522164493800_bqaf178-B28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"2026050522164493800_bqaf178-B29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.113.01803","article-title":"Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone\/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure","volume":"63","author":"Rickard","year":"2014","journal-title":"Hypertension"},{"issue":"1","key":"2026050522164493800_bqaf178-B30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/HYPERTENSIONAHA.115.05674","article-title":"Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice","volume":"66","author":"DeMarco","year":"2015","journal-title":"Hypertension"},{"issue":"8","key":"2026050522164493800_bqaf178-B31","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1210\/en.2016-1040","article-title":"Cardiac tissue injury and remodeling is dependent upon MR regulation of activation pathways in cardiac tissue macrophages","volume":"157","author":"Shen","year":"2016","journal-title":"Endocrinology"},{"issue":"2","key":"2026050522164493800_bqaf178-B32","doi-asserted-by":"crossref","first-page":"e007279","DOI":"10.1161\/CIRCHEARTFAILURE.120.007279","article-title":"Mineralocorticoid receptor in smooth muscle contributes to pressure overload-induced heart failure","volume":"14","author":"Kim","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"9","key":"2026050522164493800_bqaf178-B33","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1210\/en.2016-1911","article-title":"Deoxycorticosterone\/salt-mediated cardiac inflammation and fibrosis are dependent on functional CLOCK signaling in male mice","volume":"158","author":"Fletcher","year":"2017","journal-title":"Endocrinology"},{"issue":"1","key":"2026050522164493800_bqaf178-B34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/JOE-18-0584","article-title":"Cardiomyocyte transcription is controlled by combined mineralocorticoid receptor and circadian clock signalling","volume":"241","author":"Fletcher","year":"2019","journal-title":"J Endocrinol"},{"issue":"3","key":"2026050522164493800_bqaf178-B35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1440-1797.2007.00796.x","article-title":"Rodent models of streptozotocin-induced diabetic nephropathy","volume":"12","author":"Tesch","year":"2007","journal-title":"Nephrology (Carlton)"},{"issue":"24","key":"2026050522164493800_bqaf178-B36","doi-asserted-by":"crossref","first-page":"9232","DOI":"10.1073\/pnas.0602956103","article-title":"Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice","volume":"103","author":"Le May","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026050522164493800_bqaf178-B37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13765-020-00547-5","article-title":"Sex differences in glucose metabolism of streptozotocin-induced diabetes inbred mice (C57BL\/6J)","volume":"63","author":"Kim","year":"2020","journal-title":"Appl Biol Chem"},{"key":"2026050522164493800_bqaf178-B38","unstructured":"Kanki M, Vivekanantham E, Tesch GH, et al \u00a02025. Kanki diabetes manuscript supplementary figures Sept 2025. Figshare. doi:106084\/m9figshare30514913. Date of deposit 3 November 2025."},{"issue":"2","key":"2026050522164493800_bqaf178-B39","doi-asserted-by":"crossref","first-page":"H241","DOI":"10.1152\/ajpheart.00390.2022","article-title":"A high-sucrose diet exacerbates the left ventricular phenotype in a high fat-fed streptozotocin rat model of diabetic cardiomyopathy","volume":"324","author":"Velagic","year":"2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"2026050522164493800_bqaf178-B40","doi-asserted-by":"crossref","first-page":"H58","DOI":"10.1152\/ajpheart.00157.2018","article-title":"Improving the quality of preclinical research echocardiography: observations, training, and guidelines for measurement","volume":"315","author":"Donner","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"2026050522164493800_bqaf178-B41","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","article-title":"Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure","volume":"54","author":"Rickard","year":"2009","journal-title":"Hypertension"},{"key":"2026050522164493800_bqaf178-B42","unstructured":"Kanki M, Vivekanantham E, Tesch GH, et al \u00a02025. Kanki diabetes manuscript endocrinology supplementary tables 1-3 2025. Figshare. doi:106084\/m9figshare30515771. Date of deposit 3 November 2025."},{"issue":"3","key":"2026050522164493800_bqaf178-B43","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/en.2013-1772","article-title":"CCL2-dependent macrophage recruitment is critical for mineralocorticoid receptor-mediated cardiac fibrosis, inflammation, and blood pressure responses in male mice","volume":"155","author":"Shen","year":"2014","journal-title":"Endocrinology"},{"issue":"1","key":"2026050522164493800_bqaf178-B44","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"Qupath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"2026050522164493800_bqaf178-B45","unstructured":"Kanki M, Vivekanantham E, Tesch GH, et al \u00a02025. Kanki diabetes manuscript, supplementary methods September 2025. Figshare. doi:106084\/m9figshare30514868. Date of deposit 3 November 2025."},{"issue":"1","key":"2026050522164493800_bqaf178-B46","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/andr.70100","article-title":"Spatial transcriptomics mapping of immune cell and TGF\u03b2 signalling pathway heterogeneity in testicular germ cell tumours","volume":"14","author":"Moody","year":"2026","journal-title":"Andrology"},{"issue":"1","key":"2026050522164493800_bqaf178-B47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"19","key":"2026050522164493800_bqaf178-B48","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"issue":"28","key":"2026050522164493800_bqaf178-B49","doi-asserted-by":"crossref","first-page":"583","DOI":"10.21105\/joss.00583","article-title":"RNAsik: a pipeline for complete and reproducible RNA-Seq analysis that runs anywhere with speed and ease","volume":"3","author":"Tsyganov","year":"2018","journal-title":"J Open Source Softw"},{"issue":"5","key":"2026050522164493800_bqaf178-B50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"2026050522164493800_bqaf178-B51","unstructured":"Kanki M, Vivekanantham E, Tesch GH, et al \u00a02025. Kanki diabetes manuscript endocrinology supplementary tables 4-6 2025. Figshare. doi:106084\/m9figshare30515810. Date of Deposit 3rd November 2025."},{"issue":"45","key":"2026050522164493800_bqaf178-B52","doi-asserted-by":"crossref","first-page":"16219","DOI":"10.1073\/pnas.1408886111","article-title":"A circadian gene expression atlas in mammals: implications for biology and medicine","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"458","key":"2026050522164493800_bqaf178-B53","doi-asserted-by":"crossref","first-page":"eaat8806","DOI":"10.1126\/scitranslmed.aat8806","article-title":"A database of tissue-specific rhythmically expressed human genes has potential applications in circadian medicine","volume":"10","author":"Ruben","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026050522164493800_bqaf178-B54","unstructured":"Kanki M, Vivekanantham E, Tesch GH, et al \u00a02025. Kanki diabetes manuscript endocrinology supplementary tables S7-S19 2025. Figshare. doi:106084\/m9figshare30515828. Date of Deposit 3 November 2025."},{"key":"2026050522164493800_bqaf178-B55","unstructured":"Kanki M, Vivekanantham E, Tesch GH, et al \u00a02025. Kanki Diabetes manuscript 2025 supplementary tables 20-23. Figshare. doi:106084\/m9figshare30515837. Date of Deposit 3 November 2025."},{"issue":"4","key":"2026050522164493800_bqaf178-B56","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00592-016-0949-7","article-title":"Cardiovascular complications of type 1 diabetes: update on the renal link","volume":"54","author":"Orchard","year":"2017","journal-title":"Acta Diabetol"},{"issue":"1","key":"2026050522164493800_bqaf178-B57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"issue":"4","key":"2026050522164493800_bqaf178-B58","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/HJH.0000000000003372","article-title":"Hyperkalemia by eplerenone or esaxerenone in the presence or absence of clarithromycin in hypertensive patients: a retrospective observational cohort study","volume":"41","author":"Hirai","year":"2023","journal-title":"J Hypertens"},{"issue":"1","key":"2026050522164493800_bqaf178-B59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1152\/physrev.00021.2009","article-title":"Inwardly rectifying potassium channels: their structure, function, and physiological roles","volume":"90","author":"Hibino","year":"2010","journal-title":"Physiol Rev"},{"issue":"3","key":"2026050522164493800_bqaf178-B60","doi-asserted-by":"crossref","first-page":"e004667","DOI":"10.1161\/CIRCEP.116.004667","article-title":"Electrophysiology of hypokalemia and hyperkalemia","volume":"10","author":"Weiss","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"3","key":"2026050522164493800_bqaf178-B61","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.kint.2019.10.016","article-title":"Noncanonical immunomodulatory activity of complement regulator C4BP(beta-) limits the development of lupus nephritis","volume":"97","author":"Luque","year":"2020","journal-title":"Kidney Int"},{"issue":"12","key":"2026050522164493800_bqaf178-B62","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2337\/db25-0282","article-title":"Trem2+ macrophages alleviate renal tubule lipid accumulation and ferroptosis in diabetic nephropathy by repressing IL-1beta-mediated CD36 expression","volume":"74","author":"Wang","year":"2025","journal-title":"Diabetes"},{"key":"2026050522164493800_bqaf178-B63","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003836","article-title":"TREM1 deficiency attenuates LPS-induced sepsis-associated acute kidney injury by modulating macrophage polarization","author":"Xu","journal-title":"Int J Surg"},{"key":"2026050522164493800_bqaf178-B64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cca.2018.03.033","article-title":"Lectin-induced renal local complement activation is involved in tubular interstitial injury in diabetic nephropathy","volume":"482","author":"Zheng","year":"2018","journal-title":"Clin Chim Acta"},{"issue":"8","key":"2026050522164493800_bqaf178-B65","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/ki.2012.226","article-title":"Signaling through the interleukin-18 receptor alpha attenuates inflammation in cisplatin-induced acute kidney injury","volume":"82","author":"Nozaki","year":"2012","journal-title":"Kidney Int"},{"issue":"4","key":"2026050522164493800_bqaf178-B66","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/ijms17040471","article-title":"The expression profile of complement components in podocytes","volume":"17","author":"Li","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026050522164493800_bqaf178-B67","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4049\/jimmunol.178.1.530","article-title":"C-reactive protein-mediated suppression of nephrotoxic nephritis: role of macrophages, complement, and Fcgamma receptors","volume":"178","author":"Rodriguez","year":"2007","journal-title":"J Immunol"},{"issue":"4","key":"2026050522164493800_bqaf178-B68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00001888-199104000-00003","article-title":"An award program for teaching excellence","volume":"66","author":"Gastel","year":"1991","journal-title":"Acad Med"},{"issue":"3","key":"2026050522164493800_bqaf178-B69","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3390\/ijms25031387","article-title":"Complement cascade proteins correlate with fibrosis and inflammation in early-stage type 1 diabetic kidney disease in the Ins2Akita mouse model","volume":"25","author":"Tserga","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026050522164493800_bqaf178-B70","doi-asserted-by":"crossref","first-page":"216568","DOI":"10.1016\/j.canlet.2023.216568","article-title":"Blocking MARCO(+) tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway","volume":"582","author":"Ding","year":"2024","journal-title":"Cancer Lett"},{"key":"2026050522164493800_bqaf178-B71","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.2147\/JIR.S488553","article-title":"GSDMD mediates Ang II-induced hypertensive nephropathy by regulating the GATA2\/AQP4 signaling pathway","volume":"17","author":"Fan","year":"2024","journal-title":"J Inflamm Res"},{"issue":"4","key":"2026050522164493800_bqaf178-B72","doi-asserted-by":"crossref","first-page":"100992","DOI":"10.1016\/j.xcrm.2023.100992","article-title":"Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution","volume":"4","author":"Balzer","year":"2023","journal-title":"Cell Rep Med"},{"issue":"1","key":"2026050522164493800_bqaf178-B73","doi-asserted-by":"crossref","first-page":"e157165","DOI":"10.1172\/JCI157165","article-title":"Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists","volume":"134","author":"Abedini","year":"2024","journal-title":"J Clin Invest"},{"issue":"4","key":"2026050522164493800_bqaf178-B74","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/HYPERTENSIONAHA.118.12198","article-title":"Diet-induced obesity promotes kidney endothelial stiffening and fibrosis dependent on the endothelial mineralocorticoid receptor","volume":"73","author":"Aroor","year":"2019","journal-title":"Hypertension"},{"issue":"2","key":"2026050522164493800_bqaf178-B75","doi-asserted-by":"crossref","first-page":"e13731","DOI":"10.1111\/apha.13731","article-title":"Endothelial mineralocorticoid receptor ablation confers protection towards endothelial dysfunction in experimental diabetes in mice","volume":"234","author":"Lyngs\u00f8","year":"2022","journal-title":"Acta Physiol (Oxf)"},{"key":"2026050522164493800_bqaf178-B76","doi-asserted-by":"crossref","first-page":"603247","DOI":"10.3389\/fphys.2020.603247","article-title":"The impact of antidiabetic therapies on diastolic dysfunction and diabetic cardiomyopathy","volume":"11","author":"Gopal","year":"2020","journal-title":"Front Physiol"},{"key":"2026050522164493800_bqaf178-B77","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fphys.2020.00124","article-title":"Defining the progression of diabetic cardiomyopathy in a mouse model of type 1 diabetes","volume":"11","author":"De Blasio","year":"2020","journal-title":"Front Physiol"},{"key":"2026050522164493800_bqaf178-B78","first-page":"5582567","article-title":"FTZ ameliorates diabetic cardiomyopathy by inhibiting inflammation and cardiac fibrosis in the streptozotocin-induced model","volume":"2021","author":"Wang","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"issue":"2","key":"2026050522164493800_bqaf178-B79","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/jmcc.2001.1504","article-title":"Alterations of the circadian clock in the heart by streptozotocin-induced diabetes","volume":"34","author":"Young","year":"2002","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"2026050522164493800_bqaf178-B80","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bbrc.2004.03.055","article-title":"Gene- and tissue-specific alterations of circadian clock gene expression in streptozotocin-induced diabetic mice under restricted feeding","volume":"317","author":"Oishi","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2026050522164493800_bqaf178-B81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1755-5922.12242","article-title":"The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin-induced diabetes","volume":"35","author":"Mayyas","year":"2017","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"2026050522164493800_bqaf178-B82","doi-asserted-by":"crossref","first-page":"H1398","DOI":"10.1152\/ajpheart.00313.2002","article-title":"Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in type 1 diabetic rats","volume":"283","author":"Choi","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026050522164493800_bqaf178-B83","doi-asserted-by":"crossref","first-page":"8454078","DOI":"10.1155\/2018\/8454078","article-title":"The pattern of mRNA expression is changed in sinoatrial node from Goto-Kakizaki type 2 diabetic rat heart","volume":"2018","author":"Howarth","year":"2018","journal-title":"J Diabetes Res"},{"issue":"7","key":"2026050522164493800_bqaf178-B84","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3390\/ijms20071680","article-title":"Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in streptozotocin-induced diabetic rats","volume":"20","author":"Lee","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2026050522164493800_bqaf178-B85","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ecl.2006.05.002","article-title":"Alterations in ion channel physiology in diabetic cardiomyopathy","volume":"35","author":"Cesario","year":"2006","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"2026050522164493800_bqaf178-B86","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"issue":"16","key":"2026050522164493800_bqaf178-B87","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.3390\/ijms20163986","article-title":"Calcium as a key player in arrhythmogenic cardiomyopathy: adhesion disorder or intracellular alteration?","volume":"20","author":"Moccia","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2026050522164493800_bqaf178-B88","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2337\/db15-0384","article-title":"ASK1 inhibitor halts progression of diabetic nephropathy in Nos3-deficient mice","volume":"64","author":"Tesch","year":"2015","journal-title":"Diabetes"},{"issue":"19","key":"2026050522164493800_bqaf178-B89","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.3390\/cells11193117","article-title":"In vivo inhibition of miR-34a modestly limits cardiac enlargement and fibrosis in a mouse model with established type 1 diabetes-induced cardiomyopathy, but does not improve diastolic function","volume":"11","author":"Bernardo","year":"2022","journal-title":"Cells"},{"issue":"11","key":"2026050522164493800_bqaf178-B90","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"issue":"1","key":"2026050522164493800_bqaf178-B91","doi-asserted-by":"crossref","first-page":"1470320319827449","DOI":"10.1177\/1470320319827449","article-title":"The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone","volume":"20","author":"Bamberg","year":"2019","journal-title":"J Renin Angiotensin Aldosterone Syst"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqaf178\/66804562\/bqaf178.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/5\/bqaf178\/66804562\/bqaf178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/5\/bqaf178\/66804562\/bqaf178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:17:34Z","timestamp":1778033854000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqaf178\/8467187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,7]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqaf178","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,2,6]]},"article-number":"bqaf178"}}